Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins.

Authors:
Shifeng Su John T Minges Gail Grossman Amanda J Blackwelder James L Mohler Elizabeth M Wilson

J Biol Chem 2013 Aug 12;288(34):24809-24. Epub 2013 Jul 12.

Laboratories for Reproductive Biology, Department of Pediatrics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA.

Melanoma antigen-A11 (MAGE-A11) is a low-abundance, primate-specific steroid receptor coregulator in normal tissues of the human reproductive tract that is expressed at higher levels in prostate cancer. Increased expression of MAGE-A11 enhances androgen receptor transcriptional activity and promotes prostate cancer cell growth. Further investigation into the mechanisms of MAGE-A11 function in prostate cancer demonstrated interactions with the retinoblastoma-related protein p107 and Rb tumor suppressor but no interaction with p130 of the Rb family. MAGE-A11 interaction with p107 was associated with transcriptional repression in cells with low MAGE-A11 and transcriptional activation in cells with higher MAGE-A11. Selective interaction of MAGE-A11 with retinoblastoma family members suggested the regulation of E2F transcription factors. MAGE-A11 stabilized p107 by inhibition of ubiquitination and linked p107 to hypophosphorylated E2F1 in association with the stabilization and activation of E2F1. The androgen receptor and MAGE-A11 modulated endogenous expression of the E2F1-regulated cyclin-dependent kinase inhibitor p27(Kip1). The ability of MAGE-A11 to increase E2F1 transcriptional activity was similar to the activity of adenovirus early oncoprotein E1A and depended on MAGE-A11 interactions with p107 and p300. The immunoreactivity of p107 and MAGE-A11 was greater in advanced prostate cancer than in benign prostate, and knockdown with small inhibitory RNA showed that p107 is a transcriptional activator in prostate cancer cells. These results suggest that MAGE-A11 is a proto-oncogene whose increased expression in prostate cancer reverses retinoblastoma-related protein p107 from a transcriptional repressor to a transcriptional activator of the androgen receptor and E2F1.

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M113.468579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750176PMC
August 2013

Publication Analysis

Top Keywords

prostate cancer
24
mage-a11
14
androgen receptor
12
p107
9
increased expression
8
transcriptional activity
8
protein p107
8
transcriptional activator
8
retinoblastoma-related protein
8
p107 transcriptional
8
melanoma antigen-a11
8
antigen-a11 mage-a11
8
prostate
7
transcriptional
7
cancer
6
e2f1
5
cancer benign
4
family members
4
retinoblastoma family
4
mage-a11 retinoblastoma
4

Similar Publications

Editorial Comment to Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.

Authors:
Shingo Hatakeyama Chikara Ohyama

Int J Urol 2021 Mar 4. Epub 2021 Mar 4.

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.

View Article and Full-Text PDF
March 2021
Similar Publications

Impact of penile rehabilitation with phosphodiesterase-5 inhibitors on recovery of erectile function in patients undergoing robot-assisted radical prostatectomy: A propensity score-matched analysis.

Authors:
Yusuke Kimura Masashi Honda Shogo Teraoka Tetsuya Yumioka Hideto Iwamoto Shuichi Morizane Katsuya Hikita Atsushi Takenaka

Int J Urol 2021 Mar 4. Epub 2021 Mar 4.

Department of Urology, Tottori University Faculty of Medicine, Yonago, Tottori, Japan.

Objective: To investigate the impact of penile rehabilitation on the recovery of erectile function after robot-assisted radical prostatectomy.

Methods: Patients who underwent robot-assisted radical prostatectomy in our department from 2010 to 2019 were included. For penile rehabilitation, a phosphodiesterase-5 inhibitor (tadalafil 20 mg) was administered twice a week for 1-6 months postoperatively. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.

Authors:
Jamal Majidpoor Keywan Mortezaee

Clin Immunol 2021 Mar 1:108707. Epub 2021 Mar 1.

Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran; Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Electronic address:

Colorectal cancer (CRC), and breast, ovarian, pancreatic and prostate cancers are generally considered as low immune-reactive cancers that represent either limited infiltration of immune cells or extensive infiltration of immunosuppressive T cells. Interaction between programmed death ligand 1 (PD-L1) with programmed death-1 receptor (PD-1) is important for immune evasion. Tumors positive for PD-L1 generally show higher responses to the immune checkpoint inhibition (ICI); however, the high presence of PD-L1 in a tumor is a predictor of poor prognosis. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.

Authors:
Laila A Gharzai Ralph Jiang David Wallington Gavin Jones Samuel Birer Neil Jairath Elizabeth M Jaworski Matthew R McFarlane Brandon A Mahal Paul L Nguyen Howard Sandler Todd M Morgan Zachery R Reichert Joshi J Alumkal Rohit Mehra Amar U Kishan Karim Fizazi Susan Halabi Edward M Schaeffer Felix Y Feng David Elliott Robert T Dess William C Jackson Matthew J Schipper Daniel E Spratt

Lancet Oncol 2021 Mar;22(3):402-410

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. Electronic address:

Background: The international Intermediate Clinical Endpoints in Cancer of the Prostate working group has established metastasis-free survival as a surrogate for overall survival in localised prostate cancer based on the findings of 19 predominantly radiotherapy-based trials. We sought to comprehensively assess aggregate trial-level performance of commonly reported intermediate clinical endpoints across all randomised trials in localised prostate cancer.

Methods: For this meta-analysis, we searched PubMed for all trials in localised or biochemically recurrent prostate cancer published between Jan 1, 1970, and Jan 15, 2020. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis.

Authors:
Zachary J Ward Andrew M Scott Hedvig Hricak Rifat Atun

Lancet Oncol 2021 Mar;22(3):341-350

Department of Global Health and Population, Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA; Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, Boston, MA, USA.

Background: In addition to increased availability of treatment modalities, advanced imaging modalities are increasingly recommended to improve global cancer care. However, estimates of the costs and benefits of investments to improve cancer survival are scarce, especially for low-income and middle-income countries (LMICs). In this analysis, we aimed to estimate the costs and lifetime health and economic benefits of scaling up imaging and treatment modality packages on cancer survival, both globally and by country income group. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap